Evidence map›Paper›PMID 31900481›Full record

ArticleThe Journal of clinical endocrinology and metabolism2020

Objective Response and Prolonged Disease Control of Advanced Adrenocortical Carcinoma with Cabozantinib.

Matthias Kroiss, Felix Megerle, Max Kurlbaum, Sebastian Zimmermann, Julia Wendler, Camilo Jimenez, Constantin Lapa, Marcus Quinkler, Oliver Scherf-Clavel, Mouhammed Amir Habra and 1 more

2 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 31 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 1 pooled it
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00453674 recruitingnot on this map

Deutsches Nebennieren-Karzinom-Register - German Adrenocortical Carcinoma Registry

TypeobservationalSponsorUniversity of WuerzburgRan2003 to 2030Enrolled1,000ConditionsAdrenocortical Carcinoma
NCT03612232 phase2unknown statusnot on this map

A Multicenter, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Cabozantinib in Advanced (Unresectable or Metastatic) Adrenocortical Carcinoma

TypeinterventionalSponsorWuerzburg University HospitalRan2019 to 2025Enrolled37ConditionsAdrenocortical CarcinomaArmsCabozantinib-s-malate
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Systemic Management of Advanced Adrenocortical Carcinoma.Current treatment options in oncology · 2024
    Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Matthias KroissDept. of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Germany.
Felix MegerleDept. of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Germany.
Max KurlbaumDept. of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Germany.
Sebastian ZimmermannCore Unit Clinical Mass Spectrometry, University Hospital Würzburg, University of Würzburg, Germany.
Julia WendlerDept. of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Germany.
Camilo JimenezThe University of Texas MD Anderson Cancer Center, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, Houston, Texas, USA.
Constantin LapaDepartment of Nuclear Medicine, University Hospital Würzburg, University of Würzburg, Germany.
Marcus QuinklerCharité University Medicine and Endokrinologie in Charlottenburg, Berlin, Germany.
Oliver Scherf-ClavelInstitute for Pharmacy and Food Chemistry, University of Würzburg, Germany.
Mouhammed Amir HabraThe University of Texas MD Anderson Cancer Center, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, Houston, Texas, USA.
Martin FassnachtDept. of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital Würzburg, University of Würzburg, Germany.
University of Würzburg · DEThe University of Texas MD Anderson Cancer Center · USCharité - Universitätsmedizin Berlin · DE

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
6 · The paper itself

Abstract

backgroundObjective response of advanced adrenocortical carcinoma (ACC) to mitotane and cytotoxic chemotherapy regimen is only ~20% and early tumor progression is frequent. Previous clinical trials with oral multikinase inhibitors were negative, which has been attributed in part to inadvertent drug interaction with mitotane. Cabozantinib (CABO) is an inhibitor of c-MET, vascular endothelial growth factor receptor 2, AXL, and RET and approved for advanced kidney cancer, liver carcinoma after previous sorafenib, and medullary thyroid carcinoma.

objectiveTo investigate the clinical efficacy and safety of CABO monotherapy in ACC patients.

designRetrospective cohort study.

settingThree referral centers for ACC (Germany, United States).

resultsSixteen patients (13 female) with progressive ACC received CABO after previous mitotane in 15/16 and 3 (median, range 0-8) further systemic treatments. Prior CABO therapy, mitotane was discontinued in all patients. Mitotane plasma concentration was <2 mg/L in 7/16 patients and discontinued >12 months in 6 additional patients before CABO use. In 4/5 cases with available plasma samples, CABO concentration was in the expected steady-state range. Adverse events of grade 1/2 and 3 were observed in 13 and 3 patients, respectively, and consistent with the known safety profile of CABO. Best response was partial response in 3, stable disease in 5, and progressive disease in 8 patients. Median progression-free and overall survival was 16 and 58 weeks, respectively.

conclusionCABO monotherapy appears to be safe and effective as a monotherapy in advanced ACC after failing prior treatments. Therefore, prospective investigation of CABO in ACC patients is warranted.

Indexed as

Progression-Free SurvivalAdrenal Cortex NeoplasmsAdrenocortical CarcinomaAdultAgedAnilidesCohort StudiesDisease ProgressionFemaleGermanyHumansMaleMiddle AgedNeoplasm StagingPyridinesRegistriesAnilidescabozantinibPyridinesACCadrenal cancercabozantinibtyrosine kinase inhibitors

Identifiers

PMID31900481
PMCPMC8204945
OpenAlexW2997137086

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.